🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Three years ago today, Dr. Reza Mehrazin and his incredible staff at Mount Sinai Hospital, including his wonderful PA, Hitasha Kalola gave me a fresh start. My family and I are forever indebted to them. They are simply the best. ❤️

Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for #RenalCellCarcinoma: brnw.ch/21wNwTu Reuben Ben-David Reza Mehrazin, MD #kcsm #gusm

Getting back from a meeting in Santiago, Chile. Met new colleagues and reconnected with old friends Dr. Juan Fulla; MD; MSc. Always nice to learn new perspectives and see how our other colleagues take care of patients across the globe. Thank you for the invitation Dr. Marcelo Kerkebe Lama @rjdominguez2

Just took the OKAT with our Society of Urologic Oncology fellows. As they say it was “humbling”… See y’all in couple of weeks #SUO24 YUO Reuben Ben-David דר ראובן בן דוד Ahmed Eraky

Thank you very much! 🙏 I owe it to my mentors such as yourself and Ash Tewari, MD Robert Uzzo Mani Menon Peter Wiklund Ithaar H. Derweesh

🤖Robotic resection of an intercavo-aortic paraganglioma at Hospital Clínico San Borja Arriarán #roboticsurgery #Health

Nice piece by Steven Monda and team in #ASCODailyNews: What Do Recent Clinical Trials Reveal About Biomarkers for Adjuvant Treatment in Localized RCC, and What’s Still Missing? dailynews.ascopubs.org/do/do-recent-c… ASCO Michigan Urology Udit Singhal, MD Todd 〽️ Morgan, MD

Congratulations Matt Galsky ! We are fortunate to work with you!

These are rare tumors, yet, still captivate our minds! The 10% rule is far away from the truth! Just published in Urologic Clinics: Current management strategies for pheochromocytoma and paraganglioma! With excellent intra-op images ⏩authors.elsevier.com/a/1kjMFLO5gSWTx Nikhil Waingankar

Our results showing comparable outcomes between AT and CNAAT, raise the question of whether adding NT provides any further survival benefit when combined with modern adjuvant regimens.

Looking forward to running this session at the #AUA25 discussing techniques in Robotic Cystectomy with intracorporeal diversions with esteemed colleagues: Peter Black Piyush Kumar Agarwal Janet Kukreja Neema Navai

Ketan K. Badani MD Mutahar Ahmed Alex Mottrie Lee Zhao Reza Mehrazin, MD Shirin Razdan, M.D. Ram Pathak, M.D. Proud to be part of this international group who are all so focused on training time next generation on SP.

Great debate at robotics theater on extended LND for bladder after SWOG S1101. Have to admit still doing this for some patients. #AUA2025 Reza Mehrazin, MD Michael Stifelman Janet Kukreja Peter Black Piyush Kumar Agarwal Saum Ghodoussipour Ryan Nelson Neema Navai

Great for preventing prolapse! Piyush Kumar Agarwal Awesome technique thanks for sharing . #AUA2025 Reza Mehrazin, MD Michael Stifelman Janet Kukreja Peter Black Saum Ghodoussipour Ryan Nelson Neema Navai

⁦⁦A wonderful meeting of minds to discuss early returns of sexual function following NS RP and hydro dissection and also SP Kidney and RPLND⁦⁦@nyc robotics⁩ ⁦⁦European Urology⁩ ⁦New York, New York!RoboticTeam⁩ ⁦Reza Mehrazin, MD⁩ ⁦Dr. John Sfakianos⁩ P Wiklund. ⁦

Preoperative ctDNA was detectable in 61% of patients with localized RCC…after surgery, 83.3% cleared ctDNA. Detectable minimal residual disease ctDNA had poor survival outcomes compared to undetectable MRD ctDNA

Thank you Challenges in Laparoscopy & Robotics ( CILR ) for showing this case! The data for robotic RPLND continues to mature … current literature has shown that it is a great option for select patients with retroperitoneal tumors!

We had the honor of graduating our first SUO fellow Reuben Ben-David and on the same day we welcomed our 4th successful match Francis Simard. It has been a true pleasure to be involved in their training! Ash Tewari, MD Dr. John Sfakianos YUO Mount Sinai Department of Urology

Can photos 🖼️ truly convey the depth of two incredible and transformative years of SUO fellowship training? YUO I was extraordinarily fortunate to train under these giants Reza Mehrazin, MD, Dr. John Sfakianos , Dr. Peter Wiklund Ash Tewari, MD of urologic oncology at

A great collaborative effort on the molecular & therapeutic landscape of non–clear cell renal carcinoma (nccRCC) — from MET-driven pRCC to SMARCB1-deficient RMC. Mount Sinai Department of Urology